Clinical relevance of pretransplant anti-HLA donor-specific antibodies: Does C1q-fixation matter?

Transplant Immunology

Volumn 29, Issue 1-4, 2013, Pages 28-33

  Crespo, Marta ^a   Torio, Alberto ^b   Mas, Virginia ^c   Redondo, Dolores ^a   Pérez Sáez, Maria J ^a   Mir, Marisa ^a   Faura, Anna ^a   Guerra, Rita ^b   Montes Ares, Olga ^b   Checa, Maria D ^b   Pascual, Julio ^a  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^c Laboratori de Referencia de Catalunya   (Spain)

Author keywords

Antibody mediated rejection; Complement; Donor specific antibody; HLA antibody; Kidney transplantation

Indexed keywords

COMPLEMENT COMPONENT C1Q; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

ACUTE GRAFT REJECTION; ADOLESCENT; ANTIBODY MEDIATED REJECTION; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL ARTICLE; COMPLEMENT FIXATION; COMPLEMENT FIXATION TEST; CONTROLLED STUDY; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AMR; ANTIBODY-MEDIATED REJECTION; CDC; COMPLEMENT; COMPLEMENT-DEPENDENT CYTOTOXIC; DONOR-SPECIFIC ANTIBODIES; DONOR-SPECIFIC ANTIBODY; DSA; HLA ANTIBODY; INTERQUARTILIC RANGE; IQR; KIDNEY TRANSPLANTATION; MEAN FLUORESCENCE INDEX; MFI; SAB; SINGLE ANTIGEN BEAD ARRAY;

ADULT; AGED; ALLOGRAFTS; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TISSUE DONORS;

EID: 84897067246     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2013.07.002     Document Type: Article

References (32)

1. Süsal C., Ovens J., Mahmoud K., Döhler B., Scherer S., Ruhenstroth A., et al. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation 2011, 91:883-887.
2. Gupta A., Iveson V., Varagunam M., Bodger S., Sinnott P., Thuraisingham R.C. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant?. Transplantation 2008, 85:1200-1204.
3. Patel A.M., Pancoska C., Mulgaonkar S., Weng F.L. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007, 7:2371-2377.
4. Higgins R., Lowe D., Hathaway M., Williams C., Lam F.T., Kashi H., et al. Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch. Transplantation 2011, 92:900-906.
5. Amico P., Hönger G., Mayr M., Steiger J., Hopfer H., Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009, 87:1681-1688.
6. Lefaucheur C., Loupy A., Hill G.S., Andrade J., Nochy D., Antoine C., et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010, 10:1398-1406.
7. Singh N., Djamali A., Lorentzen D., Pirsch J.D., Leverson G., Neidlinger N., et al. Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes. Transplantation 2010, 90:1079-1084.
8. Willicombe M., Brookes P., Santos-Nunez E., Galliford J., Ballow A., Mclean A., et al. Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2011, 11:470-477.
9. Caro-Oleas J.L., González-Escribano M.F., González-Roncero F.M., Acevedo-Calado M.J., Cabello-Chaves V., Gentil-Govantes M.Á., et al. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. Nephrol Dial Transplant 2012, 27:1231-1238.
10. Mohan S., Palanisamy A., Tsapepas D., Tanriover B., Crew R.J., Dube G., et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012, 23:2061-2071.
11. Ziemann M., Schönemann C., Bern C., Lachmann N., Nitschke M., Fricke L., et al. Prognostic value and cost-effectiveness of different screening strategies for HLA antibodies prior to kidney transplantation. Clin Transplant 2012, 26:644-656.
12. Gloor J.M., Cosio F.G., Rea D.J., Wadei H.M., Winters J.L., Moore S.B., et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006, 6:1841-1847.
13. Wahrmann M., Exner M., Haidbauer B., Schillinger M., Regele H., Körmöczi G., et al. [C4d]FlowPRA screening-a specific assay for selective detection of complement-activating anti-HLA alloantibodies. Hum Immunol 2005, 66:526-534.
14. Smith J.D., Hamour I.M., Banner N.R., Rose M.L. C4d fixing, luminex binding antibodies: a new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007, 7:2809-2815.
15. Bartel G., Wahrmann M., Exner M., Regele H., Huttary N., Schillinger M., et al. In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Am J Transplant 2008, 8:41-49.
16. Bartel G., Wahrmann M., Schwaiger E., Kikic Z., Winzer C., Hörl W.H., et al. Solid phase detection of C4d-fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients. Transpl Int 2013, 26:121-130.
17. Yabu J.M., Higgins J.P., Chen G., Sequeira F., Busque S., Tyan D.B. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011, 91:342-347.
18. Chen G., Sequeira F., Tyan D.B. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011, 72:849-858.
19. Chin C., Chen G., Sequeria F., Berry G., Siehr S., Bernstein D., et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 2012, 30:158-163.
20. Sutherland S.M., Chen G., Sequeira F.A., Lou C.D., Alexander S.R., Tyan D.B. Complement-fixing donor specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 2012, 16:12-17.
21. Zeevi A., Marrari M., Feingold B., Webber S., Duquesnoy R.J. Human leukocyte antigen epitope analysis to assess complement- and noncomplement-binding donor-specific antibody repertoire in a pediatric heart transplant recipient. Hum Immunol 2012, 73:48-51.
22. Otten H.G., Verhaar M.C., Borsta H.P.E., Heneb R.J., van Zuilenb A.D. Pretransplant donor-specific HLA Class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012, 12:1618-1623.
23. Ata P., Canbakan M., Kara M., Özel L., Ünal E., Titiz M.I. Serum flow cytometric C1q binding antibody analysis of renal recipients with low levels of sensitization. Transplant Proc 2012, 44:1652-1655.
24. Lawrence C., Willicombe M., Brookes P.A., Santos-Nunez E., Bajaj R., Cook T., et al. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts. Transplantation 2013, 95:341-346.
25. Llorente S., Boix F., Eguia J., López M., Bosch A., Martinez H., et al. C1q-fixing human leukocyte antigen assay in immunized renal patients: correlation between luminex SAB-C1q and SAB-IgG. Transplant Proc 2012, 44:2535-2537.
26. Halloran P.F., Schlaut J., Solez K., Srinivasa N.S. The significance of anti-class I antibody response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992, 53:550-555.
27. Crespo M., Pascual M., Tolkoff-Rubin N., Mauiyyedi S., Collins A.B., Fitzpatrick D., et al. Incidence and characteristics of acute humoral rejection (AHR) in renal allograft recipients. Transplantation 2001, 71:652-658.
28. Dar W., Agarwal A., Watkins C., Gebel H.M., Bray R.A., Kokko K.E., et al. Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transplant 2011, 11:841-847.
29. Bentall A., Cornell L.D., Gloor J.M., Park W.D., Gandhi M.J., Winters J.L., et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013, 13:76-85.
30. Kimball P.M., Baker M.A., Wagner M.B., King A. Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection. Kidney Int 2011, 79:1131-1137.
31. Lachmann N., Terasaki P.I., Budde K., Liefeldt L., Kahl A., Reinke P., et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009, 87:1505-1513.
32. Ntokou I.S., Iniotaki A.G., Kontou E.N., Darema M.N., Apostolaki M.D., Kostakis A.G., et al. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules. Transpl Int 2011, 24:1084-1093.